Literature DB >> 12885274

Cellular FLICE-inhibitory protein: an attractive therapeutic target?

Olivier Micheau1.   

Abstract

Cellular FLIP (c-FLIP), also known as FLICE-inhibitory protein, has been identified as an inhibitor of apoptosis triggered by engagement of death receptors (DRs) such as Fas or TRAIL (TNF-related apoptosis-inducing ligand). cFLIP is recruited to DR signalling complexes, where it prevents caspase activation. Animal models have indicated that c-FLIP plays an important role in T cell proliferation and heart development. Abnormal c-FLIP expression has been identified in various diseases such as multiple sclerosis (MS), Alzheimer's disease (AD), diabetes mellitus, rheumatoid arthritis (RA) and various cancers. This review focuses on recent insights into c-FLIP dysregulation associated with human diseases and addresses the possibilities of using c-FLIP as a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12885274      PMCID: PMC2984612          DOI: 10.1517/14728222.7.4.559

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  205 in total

1.  Role of Fas--FasL interactions in the pathogenesis and regulation of autoimmune demyelinating disease.

Authors:  K A Sabelko-Downes; J H Russell; A H Cross
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

Review 2.  Defective death receptor signaling as a cause of tumor immune escape.

Authors:  Lars E French; Jürg Tschopp
Journal:  Semin Cancer Biol       Date:  2002-02       Impact factor: 15.707

3.  Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.

Authors:  M Nagane; G Pan; J J Weddle; V M Dixit; W K Cavenee; H J Huang
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

4.  Autoimmunity as a consequence of retrovirus-mediated expression of C-FLIP in lymphocytes.

Authors:  L Van Parijs; Y Refaeli; A K Abbas; D Baltimore
Journal:  Immunity       Date:  1999-12       Impact factor: 31.745

5.  Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.

Authors:  B Gliniak; T Le
Journal:  Cancer Res       Date:  1999-12-15       Impact factor: 12.701

6.  Expression of cellular FLICE-inhibitory protein in human coronary arteries and in a rat vascular injury model.

Authors:  T Imanishi; J McBride; Q Ho; K D O'Brien; S M Schwartz; D K Han
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

Review 7.  Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches.

Authors:  C L Wellington; M R Hayden
Journal:  Clin Genet       Date:  2000-01       Impact factor: 4.438

8.  Expression of Fas ligand in arteries of hypercholesterolemic rabbits accelerates atherosclerotic lesion formation.

Authors:  D B Schneider; G Vassalli; S Wen; R M Driscoll; A B Sassani; M B DeYoung; R Linnemann; R Virmani; D A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-02       Impact factor: 8.311

9.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression.

Authors:  K Song; Y Chen; R Göke; A Wilmen; C Seidel; A Göke; B Hilliard; Y Chen
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

10.  Caspase activation is required for T cell proliferation.

Authors:  N J Kennedy; T Kataoka; J Tschopp; R C Budd
Journal:  J Exp Med       Date:  1999-12-20       Impact factor: 14.307

View more
  39 in total

1.  Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis.

Authors:  M Bentele; I Lavrik; M Ulrich; S Stösser; D W Heermann; H Kalthoff; P H Krammer; R Eils
Journal:  J Cell Biol       Date:  2004-09-13       Impact factor: 10.539

2.  Fas determines differential fates of resident and recruited macrophages during resolution of acute lung injury.

Authors:  William J Janssen; Lea Barthel; Alaina Muldrow; Rebecca E Oberley-Deegan; Mark T Kearns; Claudia Jakubzick; Peter M Henson
Journal:  Am J Respir Crit Care Med       Date:  2011-09-01       Impact factor: 21.405

3.  Cellular stress responses: cell survival and cell death.

Authors:  Simone Fulda; Adrienne M Gorman; Osamu Hori; Afshin Samali
Journal:  Int J Cell Biol       Date:  2010-02-21

4.  cFLIP is critical for oligodendrocyte protection from inflammation.

Authors:  D C Tanner; A Campbell; K M O'Banion; M Noble; M Mayer-Pröschel
Journal:  Cell Death Differ       Date:  2015-01-30       Impact factor: 15.828

5.  Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5.

Authors:  Tai-Guang Jin; Alexei Kurakin; Nordine Benhaga; Karon Abe; Mehrdad Mohseni; Ferry Sandra; Keli Song; Brian K Kay; Roya Khosravi-Far
Journal:  J Biol Chem       Date:  2004-10-14       Impact factor: 5.157

6.  Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.

Authors:  Bernhard Gillissen; Jana Wendt; Antje Richter; Anja Richter; Annika Müer; Tim Overkamp; Nina Gebhardt; Robert Preissner; Claus Belka; Bernd Dörken; Peter T Daniel
Journal:  J Cell Biol       Date:  2010-03-22       Impact factor: 10.539

7.  Evasion of apoptosis as a cellular stress response in cancer.

Authors:  Simone Fulda
Journal:  Int J Cell Biol       Date:  2010-02-18

Review 8.  c-FLIP, a master anti-apoptotic regulator.

Authors:  A R Safa
Journal:  Exp Oncol       Date:  2012-10

9.  Betulinic Acid for cancer treatment and prevention.

Authors:  Simone Fulda
Journal:  Int J Mol Sci       Date:  2008-06-27       Impact factor: 6.208

10.  Computational systems biology in cancer: modeling methods and applications.

Authors:  Wayne Materi; David S Wishart
Journal:  Gene Regul Syst Bio       Date:  2007-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.